Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Acute Effects of Dietary Carbohydrate Restriction on Glycemia, Lipemia and Appetite Regulating Hormones in Normal-Weight to Obese Subjects.

Samkani A, Skytte MJ, Thomsen MN, Astrup A, Deacon CF, Holst JJ, Madsbad S, Rehfeld JF, Krarup T, Haugaard SB.

Nutrients. 2018 Sep 12;10(9). pii: E1285. doi: 10.3390/nu10091285.

2.

A carbohydrate-reduced high-protein diet acutely decreases postprandial and diurnal glucose excursions in type 2 diabetes patients.

Samkani A, Skytte MJ, Kandel D, Kjaer S, Astrup A, Deacon CF, Holst JJ, Madsbad S, Rehfeld JF, Haugaard SB, Krarup T.

Br J Nutr. 2018 Apr;119(8):910-917. doi: 10.1017/S0007114518000521.

PMID:
29644957
3.

Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial.

Lundby-Christensen L, Vaag A, Tarnow L, Almdal TP, Lund SS, Wetterslev J, Gluud C, Boesgaard TW, Wiinberg N, Perrild H, Krarup T, Snorgaard O, Gade-Rasmussen B, Thorsteinsson B, Røder M, Mathiesen ER, Jensen T, Vestergaard H, Hedetoft C, Breum L, Duun E, Sneppen SB, Pedersen O, Hemmingsen B, Carstensen B, Madsbad S.

BMJ Open. 2016 Feb 25;6(2):e008377. doi: 10.1136/bmjopen-2015-008377.

4.

Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus-the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial.

Lundby-Christensen L, Tarnow L, Boesgaard TW, Lund SS, Wiinberg N, Perrild H, Krarup T, Snorgaard O, Gade-Rasmussen B, Thorsteinsson B, Røder M, Mathiesen ER, Jensen T, Vestergaard H, Hedetoft C, Breum L, Duun E, Sneppen SB, Pedersen O, Hemmingsen B, Carstensen B, Madsbad S, Gluud C, Wetterslev J, Vaag A, Almdal TP.

BMJ Open. 2016 Feb 25;6(2):e008376. doi: 10.1136/bmjopen-2015-008376.

5.

Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance.

Eriksen M, Jensen DH, Tribler S, Holst JJ, Madsbad S, Krarup T.

Diabetologia. 2015 May;58(5):920-8. doi: 10.1007/s00125-015-3522-y. Epub 2015 Mar 9.

PMID:
25748606
6.

Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base.

Feinman RD, Pogozelski WK, Astrup A, Bernstein RK, Fine EJ, Westman EC, Accurso A, Frassetto L, Gower BA, McFarlane SI, Nielsen JV, Krarup T, Saslow L, Roth KS, Vernon MC, Volek JS, Wilshire GB, Dahlqvist A, Sundberg R, Childers A, Morrison K, Manninen AH, Dashti HM, Wood RJ, Wortman J, Worm N.

Nutrition. 2015 Jan;31(1):1-13. doi: 10.1016/j.nut.2014.06.011. Epub 2014 Jul 16. Review.

7.

Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report.

Knop FK, Lund A, Madsbad S, Holst JJ, Krarup T, Vilsbøll T.

BMC Res Notes. 2014 May 31;7:326. doi: 10.1186/1756-0500-7-326.

8.

Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study.

Reaney M, Mathieu C, Ostenson CG, Matthaei S, Krarup T, Kiljański J, Salaun-Martin C, Sapin H, Theodorakis M, Guerci B.

Health Qual Life Outcomes. 2013 Dec 26;11:217. doi: 10.1186/1477-7525-11-217.

9.

Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE.

Mathieu C, Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, Kiljański J, Salaun-Martin C, Sapin H, Theodorakis M.

Diabetes Ther. 2013 Dec;4(2):285-308. doi: 10.1007/s13300-013-0037-8. Epub 2013 Sep 10.

10.

Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study.

Kiiskinen U, Matthaei S, Reaney M, Mathieu C, Ostenson CG, Krarup T, Theodorakis M, Kiljański J, Salaun-Martin C, Sapin H, Guerci B.

Clinicoecon Outcomes Res. 2013 Jul 11;5:355-67. doi: 10.2147/CEOR.S44060. Print 2013.

11.

Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries.

Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, Kiljanski J, Salaun-Martin C, Sapin H, Bruhn D, Mathieu C, Theodorakis M.

Diabetes Metab Syndr Obes. 2013 Apr 26;6:171-85. doi: 10.2147/DMSO.S41827. Print 2013.

12.

Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study.

Matthaei S, Reaney M, Mathieu C, Ostenson CG, Krarup T, Guerci B, Kiljanski J, Petto H, Bruhn D, Theodorakis M.

Diabetes Ther. 2012 Nov;3(1):6. doi: 10.1007/s13300-012-0006-7. Epub 2012 Jun 20.

13.

Increased levels of YKL-40 and interleukin 6 in patients with chronic pancreatitis and secondary diabetes.

Hansen M, Nielsen AR, Vilsbøll T, Lund A, Krarup T, Knop FK, Vestergaard H.

Pancreas. 2012 Nov;41(8):1316-8. doi: 10.1097/MPA.0b013e31824d9b93.

PMID:
22647735
14.

Do patients with type 2 diabetes mellitus have an increased prevalence of Cushing's syndrome?

Krarup T, Krarup T, Hagen C.

Diabetes Metab Res Rev. 2012 Mar;28(3):219-27. doi: 10.1002/dmrr.2262. Review.

PMID:
22162117
15.

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.

Kielgast U, Krarup T, Holst JJ, Madsbad S.

Diabetes Care. 2011 Jul;34(7):1463-8. doi: 10.2337/dc11-0096. Epub 2011 May 18.

16.

Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.

Holst JJ, Knop FK, Vilsbøll T, Krarup T, Madsbad S.

Diabetes Care. 2011 May;34 Suppl 2:S251-7. doi: 10.2337/dc11-s227. Review. No abstract available.

17.

[Reporting adverse reactions and events in randomised clinical trials].

Hemmingsen B, Støy L, Wetterslev J, Tarnow L, Friis KB, Christensen LL, Sales N, Gluud C; Copenhagen Insulin Metformin Therapy Trial-Gruppen.

Ugeskr Laeger. 2010 Aug 30;172(35):2381-4. Danish.

PMID:
20825743
18.
19.

Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes.

Christensen M, Knop FK, Vilsbøll T, Aaboe K, Holst JJ, Madsbad S, Krarup T.

Regul Pept. 2010 Aug 9;163(1-3):96-101. doi: 10.1016/j.regpep.2010.05.004. Epub 2010 May 24.

PMID:
20580750
20.

KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.

Aaboe K, Knop FK, Vilsboll T, Vølund A, Simonsen U, Deacon CF, Madsbad S, Holst JJ, Krarup T.

J Clin Endocrinol Metab. 2009 Feb;94(2):603-8. doi: 10.1210/jc.2008-1731. Epub 2008 Dec 2.

PMID:
19050053

Supplemental Content

Loading ...
Support Center